Holen Sie sich die Stockscreener-App
103.22
1.37%
1.40
Handel nachbörslich:
103.25
0.03
+0.03%
Schlusskurs vom Vortag:
$101.82
Offen:
$102.16
24-Stunden-Volumen:
1.25M
Relative Volume:
0.60
Marktkapitalisierung:
$20.45B
Einnahmen:
$7.68B
Nettoeinkommen (Verlust:
$903.80M
KGV:
23.20
EPS:
4.45
Netto-Cashflow:
$1.14B
1W Leistung:
+13.24%
1M Leistung:
+10.05%
6M Leistung:
+3.31%
1J Leistung:
-5.57%
1-Tages-Spanne:
$101.75
$103.57
1-Wochen-Bereich:
$95.00
$103.57
52-Wochen-Spanne:
$89.24
$116.71
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Firmenname
Zimmer Biomet Holdings Inc
Sektor
Branche
Telefon
(574) 267-6131
Adresse
345 EAST MAIN STREET, WARSAW, IN
Vergleichen Sie ZBH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
103.22 | 20.17B | 7.68B | 903.80M | 1.14B | 4.45 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Hochstufung | Roth Capital | Neutral → Buy |
| 2024-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-10 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-21 | Hochstufung | Argus | Hold → Buy |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-10-20 | Eingeleitet | ROTH MKM | Neutral |
| 2023-08-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-05-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-03-29 | Eingeleitet | UBS | Sell |
| 2023-03-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-01-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Underweight |
| 2022-10-12 | Eingeleitet | Jefferies | Underperform |
| 2022-05-27 | Herabstufung | Needham | Buy → Hold |
| 2022-04-13 | Herabstufung | Truist | Buy → Hold |
| 2022-04-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
| 2022-03-02 | Herabstufung | Loop Capital | Buy → Hold |
| 2022-02-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-08 | Bestätigt | Citigroup | Buy |
| 2022-02-08 | Bestätigt | Deutsche Bank | Hold |
| 2022-02-08 | Bestätigt | JMP Securities | Mkt Outperform |
| 2022-02-08 | Bestätigt | JP Morgan | Neutral |
| 2022-02-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-08 | Bestätigt | Stifel | Buy |
| 2022-02-08 | Bestätigt | Truist | Buy |
| 2022-02-08 | Bestätigt | UBS | Neutral |
| 2022-02-08 | Bestätigt | Wells Fargo | Underweight |
| 2022-02-02 | Herabstufung | UBS | Buy → Neutral |
| 2022-01-19 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-12-09 | Herabstufung | Needham | Strong Buy → Buy |
| 2021-12-07 | Eingeleitet | Loop Capital | Buy |
| 2021-11-23 | Herabstufung | Argus | Buy → Hold |
| 2021-09-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-09 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-18 | Bestätigt | Needham | Strong Buy |
| 2020-10-20 | Eingeleitet | Northland Capital | Market Perform |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-08-05 | Bestätigt | Needham | Strong Buy |
| 2020-04-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-04-07 | Bestätigt | Needham | Strong Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-07 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2020-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2019-12-04 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-10-07 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-09-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-08-12 | Hochstufung | Argus | Hold → Buy |
| 2019-07-30 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-06-11 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2019-04-24 | Hochstufung | Needham | Buy → Strong Buy |
Alle ansehen
Zimmer Biomet Holdings Inc Aktie (ZBH) Neueste Nachrichten
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term - Yahoo Finance
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q2 2025 Earnings Call Transcript - MSN
Is Zimmer Biomet Holdings Inc. stock forming a cup and handleHigh Conviction Technical Setups - classian.co.kr
Needham Maintains a Neutral Stance on Zimmer Biomet Holdings (ZBH) - MSN
Zimmer (ZBH) Builds Robotics Growth Pipeline, but BofA Sees Limited Near-Term Upside - MSN
Zimmer Biomet (ZBH) Jumps After Raising 2025 Outlook on Strong Hip and Knee Sales—Is Momentum Sustainable? - simplywall.st
Healthcare Sector Analysts Weigh In on Sangamo Biosciences, Pliant Therapeutics, and Zimmer Biomet Holdings - AInvest
What You Need To Know Ahead of Zimmer Biomet's Earnings Release - MSN
Zimmer Biomet Acquires Monogram Technologies, Boosting Robotics Growth Pipeline, but BofA Sees Limited Near-Term Upside - AInvest
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $96 to $138 - 富途牛牛
While shareholders of Zimmer Biomet Holdings (NYSE:ZBH) are in the red over the last five years, underlying earnings have actually grown - simplywall.st
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MSN
Zimmer Biomet Holdings Maintains Hold Rating Amid Volatility Concerns - AInvest
Zimmer Biomet Surges Despite 404th-Ranked Liquidity as Earnings Outperform and UBS Maintains Sell Rating - AInvest
UBS Raises Price Target for Zimmer Biomet Holdings (ZBH) to $96 | ZBH Stock News - GuruFocus
RBC Capital Raises Zimmer Biomet PT to $115, Maintains Outperform Rating - AInvest
UBS maintains Sell rating, raises Zimmer Biomet PT to $96 from $91. - AInvest
Morgan Stanley Raises Price Target on Zimmer Biomet to $100 From $95 - MarketScreener
Raymond James maintains Outperform rating on Zimmer Biomet with new PT of $113. - AInvest
Zimmer Biomet Holdings, Inc. shares fall 1.09% intraday as brokerages adjust price targets and global growth concerns persist. - AInvest
RBC Raises Price Target on Zimmer Biomet Holdings to $115 From $112, Keeps Outperform Rating - MarketScreener
Zimmer Biomet price target raised to $113 from $104 at Raymond James - TipRanks
UBS Hikes Price Target on Zimmer Biomet to $96 From $91, Maintains Sell Rating - MarketScreener
Bernstein raises Zimmer Biomet stock price target to $105 on improving outlook - Investing.com Canada
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $95 to $138 - 富途牛牛
Zimmer Biomet Boosts 2025 Outlook on Strong Portfolio Growth and Reduced Tariff Impacts - AInvest
Zimmer Biomet price target raised to $96 from $91 at UBS - TipRanks
Zimmer Biomet raises 2025 outlook amid strong portfolio growth - Yahoo Finance
Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance
Zimmer Biomet Holdings: Balancing Strong Segment Growth with US Knee Challenges – Hold Rating Maintained - TipRanks
Zimmer Biomet Q2 2025 net sales up 7% to USD 2.077B - Medical Buyer
Jefferies Adjusts Price Target on Zimmer Biomet to $110 From $103, Maintains Hold Rating - MarketScreener
Bernstein Adjusts Price Target on Zimmer Biomet to $105 From $100, Maintains Market Perform Rating - MarketScreener
JPMorgan Adjusts Price Target on Zimmer Biomet to $115 From $105, Maintains Overweight Rating - MarketScreener
Spinal Fusion Devices Market Outlook Report 2025-2029: Revenues to Grow by $2.9 Billion Driven by Rising Spinal Disorders, Technological Advances, and Increasing Device Launches - GlobeNewswire Inc.
Zimmer: Q2 Earnings Snapshot - Connecticut Post
Zimmer Biomet Reports Strong Q2 2025 Results - TipRanks
Zimmer Biomet Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Zimmer Biomet Surges 7.99% on Revised Earnings and Tariff Relief Ranks 287th in $420M Volume - AInvest
Zimmer Biomet Reports Q2 Earnings, Raises Full-Year Outlook - InkFreeNews.com
Zimmer Biomet Holdings: Hold Rating Maintained Amid Stable Growth and Second-Half Optimism - TipRanks
Zimmer Biomet raises annual profit forecast on strong demand for medical devices - WKZO
Zimmer Biomet Holdings: Hold Rating Maintained Amid Modest Growth and Market Shifts - TipRanks
Zimmer Biomet price target raised to $138 from $135 at Roth Capital - TipRanks
Zimmer Biomet Exceeds Q2 Expectations with 7% YoY Revenue Growth - AInvest
Zimmer Biomet (NYSE:ZBH) Exceeds Q2 Expectations, Stock Soars - Yahoo Finance
Zimmer Biomet raises annual profit forecast on lower tariff impact - MSN
ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up - The Globe and Mail
Zimmer Biomet Flexes Strong Q2, Raises 2025 OutlookZimmer Biomet Holdings (NYSE:ZBH) - Benzinga
Zimmer Biomet posts Q2 beats, raises EPS guidance - MassDevice
Transcript : Zimmer Biomet Holdings, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Finanzdaten der Zimmer Biomet Holdings Inc-Aktie (ZBH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):